Selected Publications

  1. Fagerholm U, Johansson M, Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research 13(9):1336-42, 1996.
  2. Fagerholm U, Lindahl A, Lennernäs H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. Journal of Pharmacy and Pharmacology 49(7):687-90, 1997.
  3. Fagerholm U, Nilsson D, Knutson L, Lennernäs H. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiologica Scandinavica 165(3):315-24, 1999.
  4. Lennernäs H, Palm K, Fagerholm U, Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. International Journal of Pharmaceutics 127:103-7, 1995.
  5. Berggren S, Hoogstraate J, Fagerholm U, Lennernäs H. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. European Journal of Pharmaceutical Sciences 21(4):553-60, 2004.
  6. Fagerholm U, Swedmark S, Breuer O, Hoogstraate J. Preclinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. Journal of Pharmacy and Pharmacology 57:587-97, 2005.
  7. Fagerholm U, Björnsson M. Clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. Journal of Pharmacy and Pharmacology 57:1539-54, 2005.
  8. Fagerholm U. Prediction of human pharmacokinetics – Evaluation of methods for prediction of hepatic metabolic clearance. Journal of Pharmacy and Pharmacology 59:803-28, 2007.
  9. Fagerholm U. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). Journal of Pharmacy and Pharmacology 59:751-7, 2007.
  10. Fagerholm U. Prediction of human pharmacokinetics – Gastrointestinal absorption. Journal of Pharmacy and Pharmacology 59:905-16, 2007.
  11. Fagerholm U. Prediction of human pharmacokinetics – Evaluation of methods for prediction of volume of distribution. Journal of Pharmacy and Pharmacology 59:1181-90, 2007.
  12. Fagerholm U. Prediction of human pharmacokinetics – Gut-wall metabolism. Journal of Pharmacy and Pharmacology 59:1335-43, 2007.
  13. Fagerholm U. Prediction of human pharmacokinetics – Suggestion on how to improve microsome-based predictions of hepatic metabolic clearance. Journal of Pharmacy and Pharmacology 59:1427-31, 2007.
  14. Fagerholm U. Prediction of human pharmacokinetics – Renal metabolic and excretion clearance. Journal of Pharmacy and Pharmacology 59:1463-71, 2007.
  15. Fagerholm U. The highly permeable blood-brain barrier: An evaluation of current opinions about brain uptake capacity. Drug Discovery Today 12:1076-82, 2007.
  16. Fagerholm U. The role of permeability in drug ADME/PK, interactions and toxicity – Presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharmaceutical Research 25:625-38, 2008.
  17. Fagerholm U. Prediction of human pharmacokinetics – Biliary and intestinal clearance and enterohepatic circulation. Journal of Pharmacy and Pharmacology 60:535-42, 2008.
  18. Fagerholm U. Presentation of a new Modified Dispersion Model (MDM) for hepatic drug extraction and new methodology for prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica 39:57-71, 2009.
  19. Hsiao Y-W, Fagerholm U, Norinder U. In silico categorization of in vivo intrinsic clearance using machine learning. Molecular Pharmaceutics 10:1318-1321, 2013.
  20. Sohlenius-Sternbeck AK, Fagerholm U, Bylund J. The volume of distribution is an indicator of poor in-vitro-in-vivo extrapolation of clearance for acidic drugs in the rat, Xenobiotica 43:671-8, 2013.
  21. Lundquist P, Lööf J, Fagerholm U, Sjögren I, Johansson J, Briem S, Hoogstraate J, Afzelius L, Andersson Prediction of rat biliary drug clearance from an in vitro hepatocyte efflux model. Drug Metabolism and Disposition 42:459-68, 2014.
  22. Fagerholm U. PK-MATRIX – a permeability:intrinsic clearance system for prediction, classification and profiling of pharmacokinetics and drug-drug interactions, 2014.

 

Leave a Reply